Question 1

What does HGH do?

Accepted Answer

Three families of outcome have a measuring instrument behind them, and each one belongs to a different diagnosis. In children short of their own growth hormone the instrument is height: in the heiGHt trial — the sponsor spells that trial name with a capital GH inside it, for growth hormone — the primary end point was annualized height velocity (AHV) at week 52, and the secondary efficacy end points included change from baseline in height SD scores (SDS). In adults wasting from HIV the instrument was what a body could still do, and a 2006 review of those patients reports that somatropin over twelve weeks effectively increased work output, bodyweight, and lean body mass, and improved health-related quality of life, compared with placebo. In adults with a shortened bowel it was the amount of intravenous feeding that could be withdrawn. There is no fourth family. Everything else a reader arrives hoping for sits outside all three instruments rather than somewhere beneath them.

Question 2

What are the benefits of HGH for men?

Accepted Answer

No benefit figure among the research behind this page is reported separately for men, so the answer starts with what stands in for one. The largest male population on record is a children's registry: the full KIGS cohort (N = 83 803 [58% male]) was treated for growth disorders, which makes it mostly boys, measured in centimetres. The adult male record is thinner again. One case report describes a 50-year-old man with hypopituitarism and T1DM who switched from somatropin to somapacitan at his request, hypopituitarism meaning a pituitary gland that has stopped making its own hormones and T1DM meaning type 1 diabetes. That report follows his blood sugar across the week rather than any benefit. The wasting work enrolled adults of both sexes and published one set of figures for the whole group. A majority inside a children's registry and a single case are not the same thing as a result in men, and the difference matters because the hoped-for benefits are adult ones.

Question 3

What is documented for women?

Accepted Answer

Three things, and the third is not what anyone expects. The registry splits its height results by sex, and the girls' row is the larger one: median gains in NAH-SDS were 1.79 (IGHD), 1.37 (ISS), and 1.34 (SGA) for boys, and 2.07 (IGHD), 1.62 (ISS), 1.07 (TS), and 1.57 (SGA) for girls, NAH-SDS meaning near-adult height scored against the population. The extra entry in the girls' row is Turner syndrome (TS; 9.2%), a chromosome condition that occurs in girls, and it exists in that table because it is one of the diagnoses growth hormone is given for. The third thing is lactation. A reference entry on somatropin in breastfeeding records that small studies by one group of investigators found that milk output increases from 19% to 36% after a 7-day course of somatropin. The same entry supplies its own limit at once, because mothers were not given extensive breastfeeding support in these studies, so what the injection adds on top of ordinary help is unmeasured. It is still the only outcome in this record measured in adult women who were not ill.

Question 4

Is HGH better for cutting or bulking?

Accepted Answer

The question assumes two directions, both measured, so that one of them can be picked. This evidence offers neither category. The single body-composition endpoint on record moves in one direction only: somatropin 0.1 mg/kg/day administered subcutaneously for 12 weeks effectively increased work output, bodyweight and lean body mass against placebo in patients with HIV-associated wasting. Weight rising was the point of that trial, because loss of body cell mass, a component of lean body mass, is associated with decreased survival in those patients. The children's record is no help either, since its instrument is height rather than shape: in the largest registry, main outcomes included adverse events (AEs), serious AEs (SAEs), and height growth. Whether any of this touches body fat, and whether it builds muscle in anyone well, are taken apart on the main HGH page. What belongs on this one is the shape of the measurement itself — a composite recorded in ill patients over twelve weeks, rather than a choice between two training goals.

Question 5

Does HGH do anything for energy or stamina?

Accepted Answer

One endpoint in this record comes close to the question, and it belongs to an illness rather than to a gym. The approval behind it is unusually explicit about what it covers, since somatropin derived from mammalian cells (Serostim) is the only US FDA-approved treatment indicated to increase lean body mass, bodyweight and physical endurance in HIV-associated wasting. Physical endurance appears there as a named outcome, which is rare. What produced it was work output on a test, measured against placebo over twelve weeks in patients who had been wasting. A second outcome travelled alongside it and is almost never quoted: health-related quality of life (HR-QOL) also improved against placebo in those same patients. Quality of life is the nearest instrument this literature holds to the thing people mean by feeling better. Then read where it was pointed. It recorded ill patients climbing back toward where they had started, rather than well adults being carried past it.

Question 6

Does HGH make an adult taller?

Accepted Answer

No, and the reason is built into the instrument rather than into the hormone. The approval sets a floor and no ceiling, covering pediatric patients at least 1 year of age (and weighing ≥ 11.5 kg) with growth failure due to inadequate secretion of endogenous growth hormone. The trials enrolled to match it, and one of them enrolled and dosed 161 treatment-naïve, prepubertal patients with GHD, prepubertal meaning before puberty had begun. The measurement then stops when growing does. A 2025 registry analysis reports its final figure at near adult height, where at NAH, height SD score (mean [SD]) was -1.21 (1.09) and -0.90 (1.20) for children with ISS and GHD, respectively. Near adult height is the point past which the instrument cannot be read again. So adult stature was not tested and found unmoved. The measuring device expires with childhood, and nothing among these sources has replaced it with one that works on a skeleton that has finished.

Question 7

What did the bowel studies count as a benefit?

Accepted Answer

The bowel work counts a benefit by subtraction. It measures how much intravenous feeding a patient no longer needs. In a randomised study of 41 people who depended on it, recipients of subcutaneous somatropin alone or somatropin plus oral glutamine had significantly greater mean reductions from baseline in weekly total IPN volume than recipients of placebo plus glutamine. IPN here is the bag a patient is fed from. Calories and the number of infusions moved the same way. All patients received a special diet, so the injection was one part of a programme rather than the whole of it. The ceiling of that benefit is worth naming. A 2014 review reports that a significant proportion of adult patients with SBS can achieve enteral autonomy, even after many years of PN dependence. SBS is short bowel syndrome, and enteral autonomy means eating enough by mouth to come off the bag. That is the largest benefit in this record, and it takes a medical burden away rather than adding to a normal life.

Question 8

Are there peptides or supplements that raise HGH?

Accepted Answer

Not in this evidence, and the distinction is worth settling before anything else. Everything measured on this page was growth hormone itself, manufactured and injected. A 2021 approval summary describes lonapegsomatropin as a long-acting prodrug of somatropin (human growth hormone), and a 2011 review records that approved copies of recombinant somatropin have gained marketing authorisation in the European Union. Those are versions of the hormone, not ways of asking a gland for more of its own. No study among the research behind this page measured an outcome for anything taken to raise natural growth hormone, so there is no benefit figure to set beside the ones above rather than a smaller figure to report. That absence is about these sources and nothing wider: the compounds sold for that purpose carry records of their own, and how they differ in kind from growth hormone is laid out at the HGH comparison page. Sermorelin's evidence sits at the Sermorelin comparison page and CJC-1295's at the CJC-1295 comparison page.

Question 9

Does an approved benefit travel to an unapproved use?

Accepted Answer

No, and this is the sentence that decides how everything above should be read. An approval is a regulator's finding about one injection, made to a filed specification and given for one named condition. Lonapegsomatropin received its first approval in August 2021 in the USA, covering pediatric patients at least 1 year of age with growth failure, which is one product and one diagnosis. A second approval covers the bowel, where recombinant growth hormone (somatropin) is now approved for clinical use in patients with short bowel syndrome (SBS). A third covers wasting in HIV. Every benefit figure on this page was produced inside one of those three, by someone who qualified to be in it. None of them is a statement about ageing, muscle or sport, and none of them attaches to a vial carrying no label. An approved benefit belongs to the approved article and to the condition it was approved for, and carrying it anywhere else manufactures a result nobody measured.

Question 10

Which hoped-for benefits were never given an endpoint?

Accepted Answer

A list serves better than a paragraph of hedging. Among these sources the outcomes with an instrument behind them are height, height velocity, bone age, blood IGF-1, lean body mass, bodyweight, work output, quality of life, milk output, and the volume of intravenous feeding a patient can stop. IGF-1 is insulin-like growth factor 1, the blood signal that climbs when growth hormone acts, and a six-year extension evaluated efficacy through annualized height velocity (AHV), change in height standard deviation score (SDS), and IGF-1 SDS. Now the second list. Sleep, skin, hair, mood, libido, recovery from training, injury repair, adult bone density and the distribution of body fat appear as endpoints in none of these sources. Even the authors of the wasting review wanted more, naming determination of longer-term efficacy and tolerability, the cost effectiveness of treatment, the optimal somatropin dosage among their open questions. Read the second list as unasked rather than as answered no. An outcome nobody pointed an instrument at has no result, which is not the same as a result of zero.

Question 11

Does the benefit continue after the injections stop?

Accepted Answer

Nothing among these sources follows anybody after the injections stop, and the way the long studies were built explains why. They are extensions, which means continuous administration by design: in the six-year extension, growth was maintained throughout pubertal development and the dose remained stable throughout the trial. What the literature does track is people stopping early, and it treats that as a failure of continuity rather than as a planned phase. A Japanese claims analysis records that high rates of discontinuation and poor adherence to treatment, which are associated with worse growth outcomes, have been documented previously, for example in the US and Europe. In one of its two databases 19% of children had stopped by 12 months and 35% by 48 months. Those are figures about who kept going, not about what stayed behind in the ones who did not. So durability has never been put to this evidence as a question, which is not the same as a benefit that fades.

Question 12

Does it work in children who are not deficient?

Accepted Answer

This is the closest the record comes to the question most adults are really asking, and it was asked in children. Idiopathic short stature means a child who is short with no measured hormone shortfall behind it. A 2025 analysis of two registries compared the two groups directly and opens by conceding that GH treatment in children with idiopathic short stature (ISS) can be controversial, and analyses comparing responses to children with GH deficiency (GHD) are limited. The effectiveness analysis set comprised 18 405 children (ISS: 2684; GHD: 15 721), 1856 of whom reached NAH. The group without a shortfall finished lower and was given more along the way, since average dose of GH was higher for children with ISS vs children with GHD but mean duration of treatment was shorter. Read the direction rather than the size of the gap. Two groups given different amounts for different lengths of time, then compared after the fact, are not a controlled test of what the shortfall contributes.

Question 13

What would a benefit in a healthy adult have to look like?

Accepted Answer

It would need an instrument, and this record holds none that would work. Every endpoint above was built around something already missing — a height score below the average for a child's age, lean mass falling away inside an illness, a bowel that cannot absorb enough. In the largest registry, safety was evaluated in all treated patients, and efficacy in those treated for 1 year or more, which is height again under another name. Point any of these at a well adult and they return nothing, because there is no deficit for them to record closing. So the gap is wider than a missing trial. Somebody would first have to agree what counts as a benefit in a body that is already working, then measure it against people who were given no hormone at all, and nothing we could find has done either. An absent instrument and a negative result are different questions, and this record contains only the first.

HGH: what the research measured